| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969525 | Vaccine | 2010 | 8 Pages |
Abstract
A formalin-inactivated West Nile Virus (WNV) vaccine (WN-VAX) derived from the WNV-NY99 strain was tested for its safety, efficacy, dilution limit for complete protection, and cross-neutralization. Safety tests performed with experimental animals, bacteria, or cultured cell lines showed no evidence of short- or long-term adverse effects. WN-VAX also protected 100% of 4-week-old mice against a lethal challenge from the WNV-NY99 strain after two doses of intraperitoneal inoculation-even when the vaccine was diluted to 3.2Â ng/dose. Moreover, very limited cross-neutralization activity against Japanese encephalitis virus, Dengue virus, Murray Valley encephalitis virus, Yellow fever virus or St. Louis encephalitis virus was observed. Therefore, the WN-VAX satisfies the requirements for human trials planned to be done in Japan.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Guillermo Posadas-Herrera, Shingo Inoue, Isao Fuke, Yuko Muraki, Cynthia A. Mapua, Afjal Hossain Khan, Maria del Carmen Parquet, Sadao Manabe, Osamu Tanishita, Toyokazu Ishikawa, Filipinas F. Natividad, Yoshinobu Okuno, Futoshi Hasebe, Kouichi Morita,